Samsung Biologics Co., Ltd. (207940)

Overview

Samsung Biologics Co., Ltd., headquartered in Incheon, South Korea, is a prominent player in the global biopharmaceutical industry. The company primarily operates through its contract development and manufacturing organization (CDMO) business, catering to clients in South Korea, Europe, the United States, and other international markets. Since its establishment in 2011, Samsung Biologics has expanded its offerings to include two main segments: CDMO, and Biopharmaceutical Development and Commercialization. The company has built a reputation for its comprehensive development services ranging from discovery to clinical manufacturing, along with its contributions to the research and commercialization of biosimilar drugs.

Products and Services

• Development Services: Samsung Biologics provides a full spectrum of development services that facilitate the journey of biopharmaceuticals from discovery to the clinic. This includes cell line development, where they create cell lines capable of producing the desired biopharmaceuticals; process development, which involves optimizing the manufacturing process for efficiency and scalability; and clinical manufacturing, where they produce clinical-grade materials for trials.
• Aseptic Filling and Lyophilization: The company offers specialized aseptic filling services to ensure that biopharmaceutical products are safely contained without any contamination. This is complemented by lyophilization (freeze-drying) services, which help in preserving the stability and extending the shelf-life of products.
• Finishing, Storage, and Shipping: Samsung Biologics takes care of the final steps in the preparation of products, from packaging to labeling. They also offer secure storage solutions and handle the logistics of shipping products to their final destinations.
• Quality Assurance and Analytical Testing Services: To maintain the highest standards of product quality, Samsung Biologics conducts thorough quality assurance and control checks. Additionally, they offer biosafety and analytical testing services to ensure compliance with regulatory requirements.
• Biosimilar Drugs Research and Commercialization: The company is actively engaged in the research and development of biosimilar drugs, which are essentially generic versions of biologic drugs that have already been approved for use. These efforts aim to provide more affordable treatment options without compromising on quality or efficacy.
• Antibody-Drug Conjugates Development and Manufacturing: Samsung Biologics is involved in the development and manufacturing of antibody-drug conjugates (ADCs), a class of highly targeted biopharmaceuticals that combine the specificity of antibodies with the potency of chemotherapy drugs.
• Mammalian and mRNA Products Manufacturing: The company has expanded its manufacturing capabilities to include both mammalian and mRNA-based products, catering to the growing demand for these advanced therapeutic products.